Lila Sciences, a Cambridge-based AI-biotech startup, raised $235 million to achieve unicorn status at over $1 billion valuation, following a $200 million seed round. It develops a “scientific superintelligence” platform integrating AI and robotic labs for accelerated drug discovery and sustainable materials. This funding reflects booming investor interest in AI-driven life sciences innovation.